All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1100+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Boston Scientific’s pulsed field ablation system nabs FDA approval
Medical device, atrial fibrillation, catheter - Read more

THE GOOD
Business Development

Sanofi commits to offloading 50% stake in Opella consumer health division to PE firm CD&R, French government also secures 2% stake
Consumer health, private equity - Read more

Angelini Pharma buys licensing rights to Cureverse’s Ph1 asset CV-01
Small molecule, epilepsy, Alzheimer’s disease - Read more

THE GOOD
Clinical Trials

Novo Nordisk’s Rybelsus cuts heart attack risk in Ph3, in diabetes patients with comorbid heart/kidney disease
Small molecule, heart disease, diabetes - Read more

Vertex Pharmaceuticals touts full Ph3 data for non-opioid pain med suzetrigine
Small molecule, pain relief, analgesic - Read more

Regenxbio showcases Ph2 data in AbbVie-partnered gene therapy ABBV-RGX-314 in wet AMD
Gene therapy, wet age-related macular degeneration (AMD) - Read more 

Nurix Therapeutics’ NX-5948 shows promise in Ph1a/1b for treating Waldenstrom’s macroglobulinaemia
Small molecule, Waldenstrom’s macroglobulinaemia - Read more

Gilead, Merck & Co.’s positive Ph2 data for lenacapavir + islatravir combo
Small molecule, human immunodeficiency virus (HIV) infection - Read more

Foresee Pharmaceuticals touts promising Ph1 safety data for linvemastat
Small molecule, autoimmune, asthma, chronic obstructive pulmonary disease (COPD) - Read more

Lykos Therapeutics’ renewed optimism as they agree with FDA on additional Ph3 trial
Small molecule, post-traumatic stress disorder, MDMA, psychedelic - Read more

THE GOOD
Earnings & Finances

Pfizer handed a “slightly less extreme” price cut recommendation for tafamidis from ICER
Small molecule, cardiomyopathy, transthyretin amyloidosis - Read more

PRESENTED BY BIO-RESEARCH.AI
Smarter, More Accessible DB Service Accelerates Future Drug Development!

Our cutting-edge AI technology processes pharma text data and builds our Deal DB, which currently includes over 25,000 global pharma-biotech deals (and growing).

Each deal provides details such as R&R, financial terms, drug profiles, clinical trial status, and even contracts.

With this DB, you can generate deal comparison tables with one click, calculate deal terms, track target trends, monitor big pharma's focus, and use keyword-based AI auto trackers. Save valuable resources with a cost-effective database.

Talk to our sales team and try out our service. Don’t miss this limited-time offer!

⬇️ More Good News ⬇️

THE GOOD
Fundraises

Seaport Therapeutics $225M Series B
Small molecule, major depressive disorder, generalized anxiety disorder - Read more

Horizon Surgical $30M Series A
Eye surgery, AI, robotic surgery - Read more

Biological Lattice Industries $1.8M Pre-Seed
Biofabrication, life science R&D - Read more

Siloton £860K ($1.12M) Seed raise
Eye scan, optometry - Read more

THE GOOD
Investments

Nucleus RadioPharma reveals site expansions on both coasts
Radiopharm, CDMO, theranostics, manufacturing - Read more

THE GOOD
IPOs

Septerna tenatively prices upcoming IPO, mid-range net haul of $157.9M
Small molecule, hypoparathyroidism - Read more

THE GOOD
Mergers & Acquisitions

Catalent’s CEO moves to calm current (and potential future) client concerns as Novo Holdings acquisition looms
CDMO, manufacturing - Read more

Cigna, Humana reportedly reignite acquisition talks
Health insurance - Read more

THE GOOD
Partnerships

Recursion expands collaboration with Google Cloud
Drug discovery, AI - Read more

Avacta Therapeutics, Tempus AI-powered drug development collab
Peptide drug conjugates, cancer, AI, drug development - Read more

GSK, Cambridge University “major” collaboration to find better ways to treat respiratory, kidney diseases
Drug discovery, R&D, respiratory diseases, kidney disease - Read more

Perseus Proteomics, UBE ADC research collab
Antibody-drug conjugate, research & development, drug discovery - Read more

Noom, Waltz Health team up on obesity management, virtual health and cost-effective GLP-1 access
Virtual health, GLP-1, obesity - Read more

THE GOOD
Politics & Policy

Biden administration proposes plan for increased contraceptive access
Contraceptive, reproductive health, patient access - Read more 

THE GOOD
Regulatory

FDA launches generic drug application transparency pilot, in bid to explain generic drug delays
Generic, approval delays - Read more [Paywall]

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Business Development

Starboard Value continues activist offensive, now secures “sizeable stake” in Johnson & Johnson consumer health spinout Kenvue
Consumer health, activist investor - Read more

THE BAD
Lawsuits

Novartis’ IRA lawsuit thrown out by New Jersey court
Inflation reduction act, drug pricing - Read more

Eli Lilly continues legal offensive over compounded/copycatted tirzepatide
GLP-1, obesity, diabetes, compounding - Read more

THE BAD
Layoffs

Takeda telegraphs further layoffs at Massachusetts site
Restructuring - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here